National trends and feasibility of a robotic surgical approach in the management of patients with inflammatory bowel disease

被引:5
|
作者
Radomski, Shannon N. [1 ]
Stem, Miloslawa [1 ]
Consul, Michael [1 ]
Maturi, Jay Rammohan [1 ]
Chung, Haniee [1 ]
Gearhart, Susan [1 ]
Graham, Ada [1 ,2 ]
Obias, Vincent J. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Colorectal Res Unit, Baltimore, MD 21205 USA
[2] Johns Hopkins Med, Natl Capital Reg, 10215 Fernwood Rd,Suite 630, Bethesda, MD 20817 USA
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2023年 / 37卷 / 10期
关键词
Robotic surgery; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; MINIMALLY INVASIVE SURGERY; PROCTECTOMY; PREVALENCE; OUTCOMES;
D O I
10.1007/s00464-023-10333-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Research on the utilization of robotic surgical approaches in the management of inflammatory bowel disease (IBD) is limited. The aims of this study were to identify temporal trends in robotic utilization and compare the safety of a robotic to laparoscopic operative approach in patients with IBD.Methods Patients who underwent minimally invasive surgery (MIS) for IBD were identified using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2013-2021). Temporal trends of robotic utilization were assessed from 2013 to 2021. Primary (30-day overall and serious morbidity) and secondary (unplanned conversion to open) outcomes were assessed between 2019 and 2021, when robotic utilization was highest. Multivariable logistic regression was performed.Results The use of a robotic approach for colectomies and proctectomies increased significantly between 2013 and 2021 (p < 0.001), regardless of disease type. A total of 6016 patients underwent MIS for IBD between 2019 and 2021. 2234 (37%) patients had surgery for UC [robotic 430 (19.3%), lap 1804 (80%)] and 3782 (63%) had surgery for CD [robotic 500 (13.2%), lap 3282 (86.8%)]. For patients with UC, there was no difference in rates of overall morbidity (22.6% vs. 20.7%, p = 0.39), serious morbidity (11.4% vs. 12.3%, p = 0.60) or conversion to open (1.5% vs. 2.1%, p = 0.38) between the laparoscopic and robotic approaches, respectively. There was no difference in overall morbidity between the two groups in patients with CD (lap 14.0% vs robotic 16.4%, p = 0.15), however the robotic group exhibited higher rates of serious morbidity (7.3% vs. 11.2%, p < 0.01), shorter LOS (3 vs. 4 days, p < 0.001) and lower rates of conversion to an open procedure (3.8% vs. 1.6%, p = 0.02). Adjusted analysis showed similar results.Conclusion The use of the robotic platform in the surgical management of IBD is increasing and is not associated with an increase in 30-day overall morbidity compared to a laparoscopic approach.
引用
收藏
页码:7849 / 7858
页数:10
相关论文
共 50 条
  • [21] The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
    Wetwittayakhlang, Panu
    Tselekouni, Paraskevi
    Al-Jabri, Reem
    Bessissow, Talat
    Lakatos, Peter L.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [22] 13-year mortality trends among hospitalized patients with inflammatory bowel disease
    Justin L Sewell
    Hal F Yee
    BMC Gastroenterology, 12
  • [23] The Role of Minimally Invasive Surgery in the Management of Inflammatory Bowel Disease: Current Trends and Future Directions
    Rathod, Sanskruti
    Kumar, Nishant
    Matiz, German D.
    Biju, Sheryl
    Girgis, Peter
    Sabu, Nagma
    Mumtaz, Hassan
    Haider, Ali
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [24] Management of inflammatory bowel disease in children: It is time for an individualised approach
    Grover, Zubin
    Alex, George
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2020, 56 (11) : 1677 - 1684
  • [25] Evaluation of Racial/Ethnic Disparities in the Surgical Management of Inflammatory Bowel Disease
    Ana Sofia Ore
    Carolina Vigna
    Anne Fabrizio
    Evangelos Messaris
    Journal of Gastrointestinal Surgery, 2022, 26 : 2559 - 2568
  • [26] Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease
    Lightner, Amy L.
    Loftus, Edward V., Jr.
    McKenna, Nicholas P.
    Raffals, Laura E.
    CURRENT DRUG TARGETS, 2019, 20 (13) : 1317 - 1322
  • [27] What Are the Targets of Inflammatory Bowel Disease Management
    Lega, Sara
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (08) : 1670 - 1675
  • [28] Inflammatory bowel disease in Mexico: Epidemiology, burden of disease, and treatment trends
    Yamamoto-Furusho, J. K.
    Bosques-Padilla, F. J.
    Charua-Guindic, L.
    Cortes-Espinosa, T.
    Miranda-Cordero, R. M.
    Saez, A.
    Ledesma-Osorio, Y.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2020, 85 (03): : 246 - 256
  • [29] Surgical Emergencies in Inflammatory Bowel Disease
    Van Eaton, John
    Hatch, Quinton M.
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (03) : 685 - 699
  • [30] Evaluating Changes in Surgical Outcomes for Patients With Inflammatory Bowel Disease Following Medicaid Expansion
    Tong, Jason K. C.
    Mascuilli, Tory
    Wirtalla, Christopher
    Aarons, Cary B.
    Saur, Nicole M.
    Mahmoud, Najjia N.
    Karakousis, Giorgos C.
    Kelz, Rachel R.
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (10) : 1579 - 1585